Check out your Company Bowl for anonymous work chats.
Sartorius has continued on its fast growth trajectory, closing the first half of 2021 with significant double-digit increases in both sales revenue and order intake.
Sartorius looks and feels different today than it did one and a half years ago. Over the past decade, the company has grown and changed significantly. Finally in 2020, we launched our sharpended brand, that now revolves around our promise "Simplifying Progress". Since then, the Sartorius Coprorate Branding and Design Team was honored with a series of branding awards for this successful transformation. Read more about the ideas and concepts behind Sartorius brand, along with the latest award wins: https://bit.ly/3r7k7OV
Sartorius announces today that it expects strong first half performance and raises its forecast for the full year of 2021. For the first six months ended June 30, the company expects revenue growth to be approximately 60% in constant currencies with an underlying EBITDA margin slightly above 34.0%.
Sartorius has acquired a majority stake in the reagent manufacturer CellGenix GmbH. The company based in Freiburg, Germany, with around 70 employees produces and markets cell culture components, such as growth factors, cytokines, and media. Sartorius plans to expand the Freiburg site substantially and to establish it as a center of excellence within the group in the areas of development and manufacture of quality critical raw materials for the cell and gene therapy market.
What does a company need to be innovative? Read the interview to find out why our Head of Research and CTO Oscar-Werner Reif believes that the crucial factor is the people, not the money – and how he wins over talented people to work for Sartorius.
Sartorius is expanding its manufacturing capabilities in Israel. Today, we opened a new 11,800-square-foot production facility in Beit Haemek and the upgraded facility already in place. The new site enables the production of advanced cell culture media, particularly for the advanced therapies market. Watch the guided tour of the facility and meet our Beit Haemek team.
Sartorius is expanding its production capabilities in Slovenia. The expanded site in Ajdovscina will contribute to the development and #manufacturing of market-leading products for #purification and analysis of large biomolecules, such as viruses, plasmids and #mRNA. These are used in vaccines as well as in cell and gene therapies and other advanced therapies.
The biopharmaceutical market is growing dynamically - and so is Sartorius. This development continuously provides new #jobs and #opportunities for those who seize them: In 2020 alone, we have created more than 1,600 jobs and welcomed more than 2,500 new colleagues. Find out more about people at Sartorius: https://bit.ly/3tRCnvD
The biopharmaceutical market is growing dynamically - and so is Sartorius. This development continuously provides new #jobs and #opportunities for those who seize them: In 2020 alone, we have created more than 1,600 jobs and welcomed more than 2,500 new colleagues. Find out more about people at Sartorius: https://bit.ly/3tRCnvD
Women in leadership positions are a self-evident fact at Sartorius. We develop our employees in all areas, from HR to marketing and sales to R&D, and encourage them to actively advance their careers. Today, 38% of our managers directly below the board level are female. Learn more about diversity at Sartorius: https://bit.ly/3tRCnvD
